Evaluation of Haemophilus influenzae Type b Vaccine for Routine Immunization in Nepali Infants

Pediatric Infectious Disease Journal

Volumn 31, Issue 4, 2012, Pages e66-e72

  Metz, Jane Astrid ^a   Hanieh, Sarah ^a   Pradhan, Rahul ^a   Joshi, Anip ^a   Shakya, Disuja ^a   Shrestha, Lochan ^a   Shrestha, Amrita ^a   Upadhyay, Bishwas ^a   Kelly, Sarah C ^a   John, Tessa M ^a   Maharjan, Bishnu Devi ^a   Yu, Ly Mee ^a   Omar, Omar ^a   Borrow, Raymond ^a   Findlow, Jamie ^a   Kelly, Dominic F ^a   Thorson, Stephen Mark ^a   Adhikari, Neelam ^a   Murdoch, David Roger ^a   Pollard, Andrew John ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Antibody persistence; Hib conjugate vaccine; Immunogenicity; Nepal

Indexed keywords

ANTIBODY; DIPHTHERIA ANTIBODY; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; POLYRIBOSYLRIBITOL PHOPHATE ANTIBODY; TETANUS ANTIBODY; TETANUS TOXOID; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; LOWEST INCOME GROUP; MALE; NEPAL; PRIORITY JOURNAL;

ANTIBODIES, BACTERIAL; CARRIER STATE; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION; INFANT; MALE; NEPAL;

EID: 84858769574     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31824a9c37     Document Type: Article

References (34)

1. WHO position paper on Haemophilus influenzae type b conjugate vaccines.Wkly Epidemiol Rec. 2011;81:445-452
2. Watt JP, Wolfson LJ, O’Brien KL, et al.Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet. 2009;374:903-911
3. Morris SK, Moss WJ, Halsey N. Haemophilus influenzae type b conjugate vaccine use and effectiveness. Lancet Infect Dis. 2008;8:435-443
4. Eskola J, Peltola H, Takala AK, et al. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy. N Engl J Med. 1987;317:717-722
5. Mulholland K, Hilton S, Adegbola R, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet. 1997;349:1191-1197
6. Booy R, Moxon ER, MacFarlane JA, et al. Efficacy of Haemophilus influenzae type B conjugate vaccine in Oxford region. Lancet. 1992;340:847
7. Vadheim CM, Greenberg DP, Partridge S, et al. Effectiveness and safety of an Haemophilus influenzae type b conjugate vaccine (PRP-T) in young infants. Kaiser-UCLA Vaccine Study Group. Pediatrics. 1993;92:272-279
8. Eskola J, Takala A, Käyhty H, et al. Experience in Finland with Haemophilus influenzae type b vaccines. Vaccine. 1991;9(suppl):S14-6 discussion S25
9. Heath PT, McVernon J. The UK Hib vaccine experience. Arch Dis Child. 2002;86:396-399
10. Talan DA, Moran GJ, Pinner RW. Progress toward eliminating Haemophilus influenzae type b disease among infants and children—United States, 19871997. Ann Emerg Med. 1999;34:109-111
11. Takala AK, Eskola J, Leinonen M, et al. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis. 1991;164:982-986
12. Murphy TV, White KE, Pastor P, et al. Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination. JAMA. 1993;269:246-248
13. GAVI Alliance. 2011. Available at: http://www.gavialliance.org/library/news/roi/2010/hib-initiative—a-gavi-success-story/ Accessed December 1, 2011.
14. Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology. 2004;113:163-174
15. Ramsay ME, McVernon J, Andrews NJ, et al. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis. 2003;188:481-485
16. Kelly DF, Moxon ER, Yu LM, et al. Anti-polyribosylribitol phosphate antibody concentrations and avidities in children since the start of Haemophilus influenzae type b immunization of infants in the United Kingdom. Clin Vaccine Immunol. 2009;16:246-252
17. Southern J, McVernon J, Gelb D, et al. Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infancy. Clin Vaccine Immunol. 2007;14:1328-1333
18. Howie SR, Antonio M, Akisanya A, et al. Re-emergence of Haemophilus influenzae type b (Hib) disease in The Gambia following successful elimination with conjugate Hib vaccine. Vaccine. 2007;25:6305-6309
19. UNICEF. Statistics, 2011. Available at: http://www.unicef.org/infobycountry/nepal_nepal_statistics.html Accessed May 1, 2011.
20. Rao R, Dhingra MS, Bavdekar S, et al. A comparison of immunogenicity and safety of indigenously developed liquid (DTwPHB-Hib) pentavalent combination vaccine (Shan 5) with Easyfive (liq) and TritanrixHB + Hiberix (lyo) in Indian infants administered according to the EPI schedule. Hum Vaccin. 2009;5:425-429
21. Kelly DF, Thorson S, Maskey M, et al. The burden of vaccine-preventable invasive bacterial infections and pneumonia in children admitted to hospital in urban Nepal. Int J Infect Dis. 2011;15:e17-e23
22. Williams EJ, Lewis J, John T, et al. Haemophilus influenzae type b carriage and novel bacterial population structure among children in urban Kathmandu, Nepal. J Clin Microbiol. 2011;49:1323-1330
23. World Health Organization, 2011. Available at: www.searo.who.int/vaccine/LinkFiles/EPI2008/Nepal08.pdf. Accessed January 21, 2011
24. Pickering JW, Martins TB, Schroder MC, et al. Comparison of a multiplex flow cytometric assay with enzyme-linked immunosorbent assay for auantitation of antibodies to tetanus, diphtheria, and Haemophilus influenzae Type b. Clin Diagn Lab Immunol. 2002;9:872-876
25. Gatchalian S, Reyes M, Bermal N, et al. A new DTPw-HBV/Hib vaccine: immune memory after primary vaccination and booster dosing in the second year of life. Hum Vaccin. 2008;4:60-66
26. Huebner RE, Nicol M, Mothupi R, et al. Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines. Vaccine. 2004;23:802-806
27. Adegbola RA, Secka O, Lahai G, et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet. 2005;366:144-150
28. von Gottberg A, de Gouveia L, Madhi SA, et al. Impact of conjugate Haemophilus influenzae type b (Hib) vaccine introduction in South Africa. Bull World Health Organ. 2006;84:811-818
29. Cowgill KD, Ndiritu M, Nyiro J, et al. Effectiveness of Haemophilus influenzae type b Conjugate vaccine introduction into routine childhood immunization in Kenya. JAMA. 2006;296:671-678
30. Lee YC, Kelly DF, Yu LM, et al. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. Clin Infect Dis. 2008;46:186-192
31. Health Protection Agency, 2008. Available at: http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/HaemophilusInfluenzaeTypeB/EpidemiologicalData/HibGraph/infectDis Accessed May 21, 2011
32. Barbour ML, Mayon-White RT, Coles C, et al. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J Infect Dis. 1995;171:93-98
33. McVernon J, Trotter CL, Slack MP, et al. Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study. BMJ. 2004;329:655-658
34. Miller E, Andrews N, Waight P, et al. Safety and immunogenicity of coadministering a combined meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine with 7-valent pneumococcal conjugate vaccine and measles, mumps, and rubella vaccine at 12 months of age. Clin Vaccine Immunol. 2011;18:367-372